Full text is available at the source.
Abstract
RNA-based therapies may provide new treatment options for inherited metabolic disorders (IMDs).
- Inherited metabolic disorders are caused by deficiencies in enzymes, transporters, or cofactors, leading to significant metabolic dysfunction.
- RNA therapies, including antisense oligonucleotides, small interfering RNAs, and messenger RNA therapeutics, aim to modulate gene expression and restore deficient proteins.
- Delivery methods for RNA therapies, such as lipid nanoparticle packaging and tissue-specific systems, are critical for their clinical application.
- The development of n-of-1 therapies has advanced personalized medicine for rare diseases, allowing for rapid and individualized drug development.
- Ongoing innovation in RNA therapy chemistries and delivery technologies is necessary to enhance their effectiveness in treating IMDs.
Simplified